Clinically optimised solutions and systems for transplantation

Facts as of March 31, 2021
NET SALES
15,1 %
EBIT
january-march 3 Msek
ACQUISITION
TIME
Lex Asea dividend from Vitrolife 2012
BURE'S OWNERSHIP STAKE
15,1 %
REPRESENTATION
FROM BURE
Gösta Johannesson (Chair)

NET ASSET VALUE
1 184 Msek
SHARE OF BURE'S NET ASSET VALUE
6,8 %

XVIVO focuses on developing optimised solutions for the preservation and perfusion of organs, tissues and cells in association with transplantation. XVIVO has more than 20 years of experience in the transplantation industry and is dedicated to providing more efficient, clinically proven and innovative products that increase the availability of acceptable donor organs and improve survival after transplantation.